Skip to main content
Autobound logo
Eli LillyPatent grant

Eli Lilly was granted a patent for LAG-3 and PD-1 antibody therapies

Read at Google Patents

Source: Autobound Signal API · 102 signals tracked for Eli Lilly · updated

Get Eli Lilly's live signals in Claude or ChatGPT, or by API

Add to Claude / ChatGPT (MCP)Get an API key: 1,000 free credits
AskWhat changed at Eli Lilly this week? Use Autobound signals for lilly.com.

What happened

In October 2026 Eli Lilly patented antibody candidates designed to activate LAG-3 alone or together with PD-1 for potential immune-system therapies.

Source

patents.google.comOct 20, 2026

US patent US12767714

LAG-3 and PD-1/LAG-3-antibodies

Abstract

The present disclosure relates to antibodies that bind to and agonize human LAG-3, and to bispecific antibodies that bind to and agonize each of human PD-1 and human LAG-3.

patents.google.com/patent/US12767714Read the full source

Extracted by Autobound

From the Signal API record
Signal
Patent grant

What this signalsA new patent often shows where a company is putting its R&D budget.

Grant date
Oct 20, 2026
Inventors
3
Patent number
US12767714
Assignee
Eli Lilly and Company

More from Eli Lilly

Company page →

More patent signals at other companies

The full record

From the Signal API record

People

  • Yaqiong LinInventor
  • Marta Antonina WitekInventor
  • Jianghuai XuInventor

Details

Primary CPC class
C07K 16/2803
USPTO assignee
Eli Lilly and Company
What the invention does
Antibodies that attach to LAG-3, including dual-target antibodies that attach to both LAG-3 and PD-1 to trigger specific immune responses.

Topics and mentions

Tags

  • Intellectual Property
  • Research & Development
  • Pharmaceuticals
  • Medical Research

Technologies named

  • antibody therapeutics
  • bispecific antibodies
  • immune checkpoint biology

Extraction

Detected
Oct 21, 2026
signal_type
patents-company
signal_subtype
patentGrant

Use this data

Get every patent signal for Eli Lilly and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Eli Lilly this week?”

    MCP setup guide

  2. Send it to your own tools

    The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.

    Signal API

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONThe record on this page and the API request

GET /v1/signals/81f36bf6-9f19-5ac3-bd4f-f3a5bb989386 returns this record as JSON. POST /v1/companies/enrich returns every signal for lilly.com.

{
  "signal_id": "81f36bf6-9f19-5ac3-bd4f-f3a5bb989386",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-10-21T15:27:06+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07K 16/2803"
      },
      {
        "code": "A61P 37/06"
      },
      {
        "code": "C07K 16/2818"
      },
      {
        "code": "C07K 2317/31"
      },
      {
        "code": "C07K 2317/622"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Medical Research"
    ],
    "detail": "In October 2026 Eli Lilly patented antibody candidates designed to activate LAG-3 alone or together with PD-1 for potential immune-system therapies.",
    "summary": "Eli Lilly was granted a patent for LAG-3 and PD-1 antibody therapies",
    "event_at": "2026-10-20",
    "inventors": [
      {
        "name": "Yaqiong Lin",
        "status": "resolved",
        "is_primary": true,
        "linkedin_url": "https://www.linkedin.com/in/yaqiong-lin-941664b8"
      },
      {
        "name": "Marta Antonina Witek",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/marta-a-witek-b262a020"
      },
      {
        "name": "Jianghuai Xu",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/jianghuai-xu-09b35a1b"
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-10-20",
    "source_url": "https://patents.google.com/patent/US12767714",
    "cpc_primary": {
      "code": "C07K 16/2803"
    },
    "patent_title": "LAG-3 and PD-1/LAG-3-antibodies",
    "patent_number": "US12767714",
    "uspto_assignee": "Eli Lilly and Company",
    "patent_abstract": "The present disclosure relates to antibodies that bind to and agonize human LAG-3, and to bispecific antibodies that bind to and agonize each of human PD-1 and human LAG-3.",
    "precision_class": "structural",
    "invention_explanation": "Antibodies that attach to LAG-3, including dual-target antibodies that attach to both LAG-3 and PD-1 to trigger specific immune responses.",
    "technologies_mentioned": [
      "antibody therapeutics",
      "bispecific antibodies",
      "immune checkpoint biology"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.